OncoSec Medical Incorporated Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

12 Months Ended

Jul. 31, 2019

Share-based Payment Arrangement [Abstract]

Schedule of Assumptions Used to Calculate Fair Value of Stock Based Compensation

The following assumptions were used for the Black-Scholes calculation of the fair value of stock-based compensation related to stock options granted during the periods presented:

	Year Ended July 31, 2019			Year Ended July 31, 2018
Expected term (years)		5.00–6.50 years			5.00–6.50 years
Risk-free interest rate		1.74 -3.09	%		1.66 – 2.90	%
Volatility		72.88 – 83.87	%		73.24 –91.99	%
Dividend yield		0	%		0	%

Summary of Stock Option Activity

The following is a summary of the Company’s 2011 Plan and non-Plan stock option activity for the years ended July 31, 2019 and 2018:

				Weighted
				Average
				Exercise
	Options			Price
Outstanding - July 31, 2017		363,941		$	19.40
Granted		628,650		$	13.80
Exercised		(25,227	)	$	12.70
Forfeited/Cancelled/Expired		(76,112	)	$	26.60
Outstanding - July 31, 2018		891,252		$	15.00
Granted		302,749		$	7.88
Exercised		(43,029	)	$	13.16
Forfeited/Cancelled		(228,700	)	$	15.32
Expired		(700	)	$	57.60
Outstanding – July 31, 2019		921,572		$	12.63
Exercisable – July 31, 2019		633,727		$	14.12

Summary of Common Stock Reserved for Future Issuance

The following table summarizes all common stock reserved for future issuance at July 31, 2019:

Common Stock options outstanding (within the 2011 Plan and outside of the terms of the 2011 Plan)			921,572
Common Stock reserved for restricted stock unit release			77,956
Common Stock authorized for future grant under the 2011 Plan			93,185
Common Stock reserved for warrant exercise			3,631,953
Commons Stock reserved for future ESPP issuance			37,608
Total common stock reserved for future issuance			4,762,274